FFO
DYN icon

Fortitude Family Office’s Dyne Therapeutics DYN Stock Holding History

Fortitude Family Office’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453 Buy
+25
New +$431 ﹤0.01% 1765

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fortitude Family Office's DYN Position: Q1 2026 in Review

Fortitude Family Office opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 25 shares worth $453. The stake represents ﹤0.01% of the portfolio and ranks #1765 among its holdings.

227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Fortitude Family Office held 25 shares of Dyne Therapeutics worth $453 as of Q1 2026.
  • Dyne Therapeutics was a new Fortitude Family Office position in Q1 2026.
  • Dyne Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1765 holding.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.